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Abstract
Hepatitis C virus (HCV) is genetically highly divergent and classified in seven major geno-
types and approximately hundred subtypes. These genotypes/subtypes have different geo-
graphic distribution and response to antiviral therapy. In Ethiopia, however, little is known
about their molecular epidemiology and genetic diversity. The aim of this study was to investi-
gate the distribution and genetic diversity of HCV genotypes/subtypes in Ethiopia, using 49
HCV RNA positive samples. HCV genotypes and subtypes were determined based on the
sequences of the core and the nonstructural protein 5B (NS5B) genomic regions. Phyloge-
netic analysis revealed that the predominant was genotype 4 (77.6%) followed by 2 (12.2%),
1 (8.2%), and 5 (2.0%). Seven subtypes were identified (1b, 1c, 2c, 4d, 4l, 4r and 4v), with 4d
(34.7%), 4r (34.7%) and 2c (12.2%) as the most frequent subtypes. Consistent with the pres-
ence of these subtypes was the identification of a potential recombinant virus. One strain was
typed as genotype 2c in the NS5B region sequence and genotype 4d in the core region. In
conclusion, genotype 4 HCV viruses, subtypes 4d and 4r, are most prevalent in Ethiopia.
This genotype is considered to be difficult to treat, thus, our finding has an important impact
on the development of treatment strategies and patient management in Ethiopia.
Introduction
Hepatitis C virus (HCV) is an important human pathogen that causes substantial morbidity and
mortality worldwide. The most recent study estimated that more than 185 million people are
chronically infected with HCV and 3–4 million new infections occur each year [1]. HCV is one
of the leading causes of end-stage liver disease, cirrhosis and hepatocellular carcinoma [2], result-
ing in over 700,000 deaths annually [3]. In addition, HCV is the most common cause of death in
HIV-positive patients on highly active antiretroviral therapy [4]. Consequently, the burden of
HCV-related morbidity and mortality will likely continue to increase over the next twenty-five
years due to the existing pool of chronic HCV infections in low-income countries [5].
HCV is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus
Hepacivirus in the family Flaviviridae. The viral genome is ~9.6 kb in length and contains a sin-
gle open reading frame that encodes a polyprotein of about 3,000 amino acids [6]. HCV shows
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extreme genetic diversity and classified into seven main genotypes (1–7), further classified into
67 confirmed, 20 provisional, and 21 unassigned subtypes [7]. The HCV genotypes differ from
each other by approximately 30–35%, and the subtypes differ from each other by at least 15%
over complete genome [7, 8]. Different HCV genotypes and subtypes display distinct geo-
graphic distribution patterns and levels of genetic diversity [6]. Overall, genotypes 1–3 are
globally distributed, causing the majority of cases in the world, whereas genotypes 4–7 are
more geographically restricted [8]. Genotype 4 is found mainly in Central Africa and the Mid-
dle East [9, 10], genotype 5 in South Africa [11], and genotype 6 in Southeast Asia [12, 13].
The recently identified genotype 7 has been isolated from a Congolese immigrant in Canada
[14]. This genetic diversity and geographic variation of HCV have an important impact on dis-
ease epidemiology and clinical practice because it is one of the most important predictors of
response to anti-viral therapy [6, 11]. Therefore, for the development of treatment strategies
and patient management, an in-depth understanding of the prevalent genotype and subtypes
in different geographic regions, including Ethiopia is highly important.
Ethiopia is a large, geographically diverse nation, home to over 100 million inhabitants.
Available data shows that its adult population has a low to moderate prevalence of HCV infec-
tions (0.52 to 5.8%) [15–17]. In Africa, distribution of HCV genotype exhibits two epidemio-
logical patterns: one characterized by high genetic diversity, distributed in West Africa, with
genotypes 1 and 2 [13, 18, 19], and the other in Central and Norther Africa, with genotype 4
[20]. However, little is known about the HCV genotype distribution in Eastern Africa in gen-
eral and in Ethiopia in particular. The only study reporting on HCV genotypes in Ethiopia was
limited to few patients attending a voluntary counseling and testing center in Addis Ababa. A
total of 18 HCV RNA positive samples were analysed and a dominance of genotype 4 (50%,
nine cases) followed by 2 (6 cases), 5 (2 cases) and 1 (1 case) was found [21]. However, no
country-wide studies have been published and information on the HCV molecular diversity
throughout the country is lacking. The aim of the present study was, therefore, to investigate
the prevalence and genetic diversity of HCV genotypes and subtypes in different geographic
regions of Ethiopia.
Materials and methods
Study area and population
This study was conducted using serum samples collected between March 2013 and April 2014
from voluntary healthy blood donors at blood bank centers in five geographic regions: Addis
Ababa (the capital, central) Adama (Oromia, central-east) Gondar (Amhara, north-west)
Mekelle (Tigray, north) and Jimma (Oromia, south-west). A total of 56,885 sera were collected,
of which 294 were tested anti-HCV antibody positive in Ethiopia [17]. Of these, 98 sera were
stored at −80˚C until use and shipped to the Netherlands for further molecular study. The
study was approved by the National Research Ethics Review Committee at the Federal Minis-
try of Science and Technology, Addis Ababa, Ethiopia. Informed written consent was given by
all participants.
Serological assays
The serological markers for HBsAg and anti-HCV antibodies were tested using commercially
available enzyme-linked immunosorbent assay ELISA kits (DIALB Diagnostics GmbH,
Vienna, Austria). Serum was also screened for anti-HIV-1 and -HIV-2 antibodies by ELISA
(Vironostika HIV Ag/Ab, Bio-Merieux, Boxtel, The Netherlands) and anti-Treponema Palli-
dum antibodies by Rapid Plasma Reagin Test (RPR) (DIALB Diagnostics GmbH, Vienna, Aus-
tria). All tests were carried out in accordance with the manufacturers’ instructions. Anti-HCV
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antibody-positive serum samples from donors co-infected either with HBV or HIV were
excluded from the present study. As the study subjects are healthy blood donors, clinical chem-
istry parameters like AST and ALT are not available.
HCV RNA extraction, RT-PCR amplification and sequencing
HCV RNA was extracted from 140μL serum using QIAamp Viral RNA mini kit (QIAGEN,
Hilden, Germany) or High Pure Viral Nucleic Acid Kit (Roche). Complementary DNA
(cDNA) was synthesized using random hexamer primers (Promega, Madison, WI, USA) and
SuperScriptIII (SSIII) First-Strand Synthesis System (Invitrogen) according to the manufactur-
ers’ instruction. Briefly, the RT reaction mixture included 10μl of viral RNA, 1μl of random
hexamers, 1μl of 40U/μl RNasin, 4μl of 5× First Strand Buffer, 2μl of 0.1M DTT, 1μl of dNTP
mix (20 mM) and 1μl (200 U/μl) SSIII reverse transcriptase; in a final volume of 20μl. A nested
PCR technique was used to amplify DNA fragments in the core and the nonstructural protein
5B (NS5B) genes. The first round of PCR was performed with 5μl cDNA in a total reaction
mixture of 50μl containing 10μl of 5× HotStar HiFidelity PCR Buffer, 1μl HotStar HiFidelity
DNA Polymerase (QIAGEN) and 1μl each forward and reverse outer primers (20 pmol/μl)
described below. The same conditions were used in the second round PCR except 2μl of first
round PCR product and 1μl each forward and reverse inner primers used here. The core gene
fragment (287–751 nt, according to the position of reference HCV isolate H77 GenBank acces-
sion number AF009606) was amplified by nested PCR with outer primers s17, 410 and inner
primers 953, 954, 951, as described previously [22] with some modifications. The NS5B gene
(8244 to 8656 nt, according to H77) was amplified by nested PCR with a combinations of
primers Pr1, Pr2, Pr3, Pr4, 122, 1204, 123 and 1203, as described previously [22, 23]. All PCR
reactions were conducted with the following thermal profile 95˚C for 5 min, then 40 cycles of
95˚C for 1 min, 48˚C/50˚C for 1 min and 72˚C for 1 min, with a final elongation step at 72˚C
for 10 min. The amplified products were gel-purified by MinElute Gel Extraction Kit (QIA-
GEN, Hilden, Germany) and bi-directionally sequenced using Big Dye Terminator v3.1 kit
and an ABI prism 3130xl auto-sequencer (Applied Biosystems, Foster City, California, USA).
HCV genotyping and phylogenetic analyses
Sequences were assembled and edited with SeqMan Pro (DNASTAR Lasergene 10). Compara-
tive analyses were performed using CLUSTAL W multiple sequence alignment program,
MEGA 6 software [24]. HCV genotypes and subtypes were determined phylogenetically by
aligning to the reference sequences retrieved from GenBank or the Los Alamos (http://hcv.
lanl.gov/content/sequence/NEWALIGN/align.html) databases and geno2pheno software
(http://www.geno2pheno.org/). Bayesian inference (BI) analyses were conducted using
MrBayes v3.2 [25]. For the construction of the Bayesian phylogeny, we selected the best model
of nucleotide substitution based on the lowest Bayesian information criterion (BIC) and
Akaike information criterion (AIC) score using TOPALi v2.5 [26]. The best model selected
was a general time reversible (GTR) with a gamma-distributed rate variation across sites and a
proportion of invariant sites (GTR+I+G). The Bayesian phylogenetic tree was constructed in
MrBayes v3.2 with GTR+I+G model using 4 chains simultaneous run for 10 million genera-
tions, a sampling frequency of 100, and a 50% burn-in. The obtained trees were visualized in
FigTree v1.4.2 [http://tree.bio.ed.ac.uk/software]. Finally, mutations in the NS5B region,
codons 230–347, were assessed by geno2pheno software (http://www.geno2pheno.org/).
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Nucleotide sequence accession numbers
The nucleotide sequences of HCV core and NS5B partial regions determined in this study
have been deposited in the GenBank sequence database, under the accession
KY627917-KY628007.
Results
Demographic characteristics
A total of 98 anti-HCV positive healthy blood donors sera (51 from Addis Ababa, 13 from
Adama, 15 from Gondar, 3 from Jimma and 16 from Mekelle) were analyzed in the present
study. Of these, 72 (73.5%) were males and 26 (26.5%) were females. The mean age was 31. 8
years (range: 18–60 years) (Table 1).
HCV genotypes and phylogenetic analysis
HCV RNA was successfully amplified in 49 of the 98 anti-HCV-positive samples. In 49 sam-
ples, even after repeated nested PCR with a combination of different primers, no genome frag-
ment could be amplified, which could be due to storage conditions, a high rate of false positive
anti-HCV antibody results or HCV clearance. Among the PCR positive samples, 42 could be
genotyped both in the NS5B and core regions, 4 in the NS5B region and 3 in the core region
only. Hence, 46 and 45 samples were successfully sequenced in the NS5B and core regions,
respectively (Table 2).
A phylogenetic tree of the NS5B region was constructed of 46 Ethiopian sequences obtained
in this work and reference sequences retrieved from GenBank. Four HCV genotypes (1, 2, 4 and
5) with seven subtypes (1b, 1c, 2c, 4d, 4l, 4r and 4v) were identified. As shown in Fig 1, the pre-
dominant was genotype 4, found in 35 strains (76.1%), followed by 2 (n = 6, 13%), 1 (n = 4,
8.7%), and 5 (n = 1, 2.2%). Of the 35 genotype 4 strains, 16 strains belong to subtype 4r, 15 strains
to 4d, 3 strains to 4l and one isolate to 4v (Table 2). All genotype 2 strains belong to subtype 2c
and 75% of genotype 1 strains to subtype 1b. All the genotypes and subtypes were confirmed by
geno2pheno software (http://www.geno2pheno.org/). A Bayesian inference phylogenetic tree for
the core region was also constructed using the 45 sequences (42 from strains used in NS5B and 3
additional strains) and reference sequences from the GenBank. The most commonly detected
genotype was genotype 4 (n = 38, 77.6%), with predominant subtypes 4d (n = 18, 36.7%) and 4r
Table 1. Demographic characteristics of blood donors enrolled in the study and PCR result (HCV-RNA).
Variables Regions Total
Addis Ababa Adama Gondar Jimma Mekelle
Sex
Male 35 (68.6%) 11 (84.6%) 13 (86.7%) 2 (66.7) 11 (68.8%) 72 (73.5%)
Female 16 (31.4%) 2 (15.4) 2 (13.3%) 1 (33.3) 5 (31.2%) 26 (26.5%)
Age, years
 20 7 (13.7%) 0 2 (13.3%) 1 (33.3%) 1 (6.2%) 11 (11.2%)
21–30 14 (27.5%) 8 (61.5%) 6 (40.0%) 0 9 (56.3%) 37 (37.6%)
31–40 20 (39.2%) 3 (23.1%) 3 (20.0%) 1 (33.3%) 5 (31.3%) 32 (32.7%)
41–50 8 (15.7%) 1 (7.7%) 4 (26.7%) 1 (33.3%) 1 (6.2%) 15 (15.3%)
> 50 2 (3.9%) 1 (7.7%) 0 0 0 3 (3.1%)
PCR
Positive 33 (64.7%) 3 (23.1%) 3 (20.0%) 2 (66.7%) 8 (50.0%) 49 (50.0%)
Negative 18 (35.3%) 10 (76.9%) 12 (80.0%) 1 (33.3%) 8 (50.0%) 49 (50.0%)
https://doi.org/10.1371/journal.pone.0179064.t001
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Table 2. Concordance of HCV genotypes/subtypes between core and NS5B regions.
Isolates Genotypes/subtypes
Core region NS5B region
AA328ETH 1b 1b
AA331ETH 1c 1c
AA332ETH 4d 4d
AA333ETH 4r 4r
AA345ETH 4d 4d
AA346ETH 4d 4d
AA347ETH 4d 4d
AA348ETH 4r 4r
AA350ETH 4d 4d
AA351ETH 4r 4r
AA352ETH 4d 4d
AA393ETH 4l 4l
AA394ETH 4r 4r
BL68ETH 4v 4v
BL78ETH NAb 4l
JM19ETH 4d 4d
MK07ETH 4r 4r
MK08ETH 4r 4r
MK32ETHa 4d 2c
MK144ETH 5a 5a
AA07ETH 4d 4d
AA44ETH 4r 4r
AA58ETH 2c 2c
AA108ETH 4d 4d
AA19ETH 4r 4r
AA148ETH 4r 4r
AA55ETH 4r 4r
AA57ETH 4l 4l
AA67ETH 4d 4d
AA71ETH NA 1b
AA214ETH 4d 4d
AA230ETH 4r 4r
AA232ETH 4d 4d
AA237ETH 4d 4d
AA174ETH 2c 2c
AA175ETH 4r 4r
AA188ETH 4r 4r
AA197ETH 4r 4r
AA239ETH 4d 4d
AA323ETH 4d 4d
GD07ETH 1b 1b
GD45ETH 2c 2c
GD93ETH NA 2c
JM05ETH 4d 4d
BL94ETH NA 2c
MK116ETH 4r 4r
(Continued )
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(n = 17, 34.7%), followed by 4l (n = 2, 4.1%) and 4v (n = 1, 2.0%). Genotype 1 (n = 3, 6.1%) com-
prised the subtypes 1b (n = 2, 4.1%) and 1c (n = 1, 2.0%). Genotype 2c was represented by 3
strains (6.1%) while one strain was classified into genotype 5a (Fig 2). Genotyping was consistent
when analyzed by either NS5B or core regions, except one strain (MK32ETH) which was 2c in
the NS5B region but 4d in the core region, suggesting the identification of a novel recombinant
HCV (Figs 1 and 2). Further full genome sequencing of this sample however failed.
Table 3 shows HCV genotype distribution in Ethiopia by age and gender. All genotype 2
strains were observed among males. Overall, no significant differences were observed between
HCV genotypes with respect to donor’s age and gender.
Mutations in NS5B region
Mutations in the NS5B region spanning amino acid codons 230–347 were investigated using
the geno2pheno software. We found that all the 46 Ethiopian sequences had mutations ranging
from one to thirteen amino acid changes (S1 Table). Interestingly, the 316N variant associated
with resistance to the direct acting antiviral Dasabuvir was detected in two subtype 1b strains
(AA328ETH and GD07ETH) (S1 Table).
Discussion
Knowledge of the HCV genotypes and subtypes has gained importance, because it plays a vital
role in predicting the therapeutic and clinical outcome of the HCV infection [6, 27]. Moreover,
the global epidemiological data show that HCV genotypes and subtypes distributions vary in
different geographic regions, even among regions of the same country [11]. However, there is
very limited information on the molecular epidemiology and genetic diversity of HCV infec-
tions in Eastern Africa including Ethiopia. In this study we report the first nationwide molecu-
lar epidemiology and genetic diversity of HCV in Ethiopia, one of the geographically diverse
and the second most populous country in Africa. We found a high level of HCV genetic diver-
sity, with four major genotypes (1, 2, 4 and 5) and seven subtypes circulating in the country.
Phylogenetic analysis revealed that the majority of Ethiopian HCV strains are belonging to
genotype 4 (78%). This genotype is the most frequent cause of chronic hepatitis C in the Mid-
dle East, Egypt and Central Africa, accounting for more than 80% of HCV infections [28]. For
instance, more than 90% of HCV infections in the Central African Republic, the Democratic
Republic of Congo, Gabon and Egypt were attributed to genotype 4 [28, 29]. In Eastern Africa,
however, due to the paucity of data the prevalence of HCV genotype 4 is currently not well
known [20]. In recent years, the epidemiology of genotype 4 has changed and this genotype
has begun spreading beyond its strongholds in Africa and the Middle East to several Western
countries, particularly in Europe, due to variations in population structure, immigration and
injection drug use (IDU) [9, 30]. For example, 10 to 24% of chronic HCV infections in
Table 2. (Continued)
Isolates Genotypes/subtypes
Core region NS5B region
MK58ETH 4r NA
MK159ETH 4d NA
MK114ETH 4d NA
aPotential recombinant virus
bNA; not available (the genomic region couldn’t be amplified for the corresponding isolate)
https://doi.org/10.1371/journal.pone.0179064.t002
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Fig 1. Bayesian inference phylogenetic tree of the NS5B region. A phylogenetic tree was constructed based on the NS5B region (356
nucleotides), corresponding to nucleotide numbering of 8288–8643 in the H77 genome, using the GTR+I+G model of evolution. Numbers on
Hepatitis C virus diversity in Ethiopia
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southern Europe, particularly in France, Italy, Greece, and Spain and 11% of chronic HCV
infections in The Netherlands were attributed to genotype 4 [9, 31, 32]. In addition, a high fre-
quency of genotype 4 (42%) was found among Somali immigrants in Minnesota, USA [33].
Nowadays, a wide-ranging overview of genotype 4 epidemiology and diversity may prove use-
ful for public health assessments not only in Africa but also outside Africa, because it accounts
for 20% of total global HCV infection [20, 31, 34]. In addition, genotype 4 is considered diffi-
cult to treat and has a poor sustained virological response rate of 43–63% to the standard pegy-
lated IFN/ribavirin combination therapy [32]. This is relatively higher than genotype 1 but
lower than genotypes, 2, 3, 5, and 6 [34, 35].
Overall, the presence of four different subtypes (4d, 4r, 4l, and 4v) of genotype 4 in Ethiopia
is indicative of a greater genetic diversity compared to HCV genotype 4 viruses reported in the
surrounding countries. In our study, subtypes 4d and 4r are the predominant subtypes,
accounting for 89% of the HCV genotype 4 infections. These subtypes are of interest because
subtype 4r is not commonly reported while 4d is mostly reported in Saudi Arabia and in the
majority of European IDU population [9, 28, 30, 36]. This result is thus different from studies
in other African countries where subtypes 4a is the predominant subtype in Egypt [28, 35], 4f
in Cameroon [37], 4e in Gabon [10, 29], 4k in the Central African Republic and Democratic
Republic of the Congo [20, 38], 4c in the Republic of Congo [39], and 4q/4v in Rwanda [20].
The high diversity and predominance of genotype 4 suggests that this genotype has been
endemic for a longer time in Ethiopian population. A previous study also showed the domi-
nance of this genotype in Ethiopia [21].
The risk factors for genotype 4 and its subtypes transmission are determined by the geo-
graphical distribution of this genotype. Intravenous drug use is the most common route of
transmission for genotype 4 infection in Europe while unsafe medical practice cause most
cases in endemic countries [35]. In Ethiopia, although we did not assess the risk concerning
genotype 4 in the present study, we suggest that sharing contaminated needles and razor blades
during tattooing, body piercing, scarification, and circumcision may be the main mode of
transmission, as these are common practices particularly in rural Ethiopia.
Genotype 2 was the second most prevalent HCV genotype in our study. HCV genotype 2
originated from Western Africa and disseminated to the globe through trans-Atlantic slave
trade, colonial history and migrations [18, 40, 41]. In Africa, it is frequently prevalent in the
west and its prevalence relative to other HCV genotypes declines from west to east [18, 41].
Our result is in agreement with the aforementioned studies. HCV genotype 2 in West Africa
exhibits high genetic diversity with several subtypes identified within this genotype [18, 40].
The HCV genotype 2 from Ethiopia was found to be less diverse and belong to a single epi-
demic subtype 2c, suggesting that it might be introduced from Western Africa to Eastern
Africa. This could be due to frequent travel of people from this geographical location to Ethio-
pia and vice versa.
Unlike hepatitis B virus [42], recombination between genotypes is not a common event in
HCV. To date, ten HCV recombinants have been identified worldwide, of which only recom-
binant 2k/1b was detected multiple times and in different countries [7, 43, 44]. In the present
study, we found that strain MK32ETH was characterized as genotype 2c in the NS5B gene (Fig
1) and genotype 4d in the core gene (Fig 2) as revealed by 3 different independent experiments.
branches are posterior probabilities from the Bayesian inference analysis. Reference sequences are labeled to the right of each branch in
the order of subtype hyphen GenBank accession number. Ethiopian sequences are shown in color (color corresponding to their geographic
origin: Red = Addis Ababa; Blue = Adama; Green = Mekelle; Pink = Gondar; Light blue = Jimma), a potential recombinant MK32ETH
highlighted in yellow.
https://doi.org/10.1371/journal.pone.0179064.g001
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Fig 2. Bayesian inference phylogenetic tree of the core region. A phylogenetic tree was constructed based on the core
region (418 nucleotides), corresponding to nucleotide numbering of 300–717 in the H77 genome, using the GTR+I+G model of
Hepatitis C virus diversity in Ethiopia
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However, although we tried to obtain the complete genome sequence as we did previously
[45], using the Bull et al. method [46], as well as 454 deep sequencing, all methods were
unsuccessful.
In conclusion, this study provides important data on HCV genotypes and subtypes in Ethi-
opia, where four main genotypes and seven subtypes were identified. HCV infection in Ethio-
pia is characterized by the predominance of HCV genotype 4 (4d and 4r), with high genetic
diversity, suggesting that this genotype has been endemic for a long time in Ethiopia. However,
further large-scale studies on the molecular epidemiology of HCV in Ethiopia are needed. As
genotype 4 is difficult to treat, our findings have a major impact in developing treatment
guidelines and patient management.
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